Curtis, D;
(2019)
A possible role for sarcosine in the management of schizophrenia.
The British Journal of Psychiatry
, 215
(6)
pp. 697-698.
10.1192/bjp.2019.194.
Preview |
Text
Curtis_SarcosineForSchizophrenia.WithSupplement.20190805.pdf - Accepted Version Download (645kB) | Preview |
Abstract
Sarcosine, which is freely sold as a dietary supplement, has pharmacological activity to boost functioning of the glutamatergic N-methyl-d-aspartate receptor (NMDAR) and hence it is a biologically rational treatment for schizophrenia. The small number of studies carried out to date provide some evidence for its efficacy and psychiatrists could consider suggesting its use to their patients.
Archive Staff Only
 |
View Item |
